Response to: Once-nightly sodium oxybate (FT218) in the treatment of narcolepsy: a letter to the editor commenting on the recent publication by C. Kushida et al.

Kushida, Clete A; Roth, Thomas; Shapiro, Colin M; Roy, Asim; Rosenberg, Russell; Ajayi, Akinyemi O; Seiden, David; Gudeman, Jennifer

Kushida, Clete A; Roth, Thomas; Shapiro, Colin M; Roy, Asim; Rosenberg, Russell; Ajayi, Akinyemi O; Seiden, David; Gudeman, Jennifer.

Afiliación

Kushida CA; Department of Psychiatry and Behavioral Sciences, Stanford University Medical Center, Palo Alto, CA, USA.
Roth T; Sleep Disorders and Research Center, Henry Ford Health System, Detroit, MI, USA.
Shapiro CM; University of Toronto, Toronto, ON, Canada.
Roy A; Ohio Sleep Medicine and Neuroscience Institute, Dublin, OH, USA.
Rosenberg R; Neurotrials Research, Inc., Atlanta, GA, USA.
Ajayi AO; Florida Pediatric Research Institute, Winter Park, FL, USA.
Seiden D; Avadel Pharmaceuticals, Chesterfield, MO, USA.
Gudeman J; Avadel Pharmaceuticals, Chesterfield, MO, USA.

Sleep ; 45(6)2022 06 13.

Article en En | MEDLINE | ID: mdl-35695179

Asunto(s)

Narcolepsia; Oxibato de Sodio; Humanos; Narcolepsia/tratamiento farmacológico; Polisomnografía; Oxibato de Sodio/uso terapéutico

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Oxibato de Sodio / Narcolepsia Límite: Humans Idioma: En Revista: Sleep Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google